RVNC - Revance Therapeutics, Inc Price Target Chart

Corporate company logo of Revance Therapeutics Inc. (RVNC)

Revance Therapeutics (RVNC) develops innovative dermatological products leveraging exclusive patents and strict FDA oversight. However, high promotion costs and potential therapy complications create significant challenges. This price chart reflects the asset's dynamics, where the indicator stands at 6.60. Future quotes will be impacted by dumping in the injectables segment, forcing the company to lower the cost of Daxxify for clinics.

RVNC (Revance Therapeutics, Inc.) Analyst Consensus Forecast history from 07/04/2022 to 02/16/2025

Analytical breakdowns for Revance Therapeutics, Inc (RVNC)

- share price and consensus valuation forecast:
Price Performance Chart revance.com|RVNC - Consensus Target
- market capitalization statistics:
Market Value Revance Therapeutics, Inc|RVNC - Total Company Value
- issuer book value statistics:
Equity per Share Revance Therapeutics|RVNC - Book Capitalization|Market Cap to Net Assets Ratio revance.com|RVNC - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Revance Therapeutics|RVNC - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Revance Therapeutics Inc|RVNC - Company Aggregate Debts|Debts to Book Capitalization Revance Therapeutics, Inc|RVNC - Company Long-Term Debt|Company Short-Term Loans and Borrowings Revance Therapeutics|Quick Liquidity Indicator revance.com
- net income and valuation multiples indicators:
RVNC - Net Profit|Projected Future Earnings Revance Therapeutics|RVNC - Price to Earnings Ratio|Future Price to Earnings Multiple Revance Therapeutics Inc.|RVNC - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Revance Therapeutics, Inc|RVNC - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Revance Therapeutics|RVNC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months revance.com|RVNC - Earnings per share growth in current year|Projected earnings per share growth rate for next year Revance Therapeutics
General company analysis:RVNC revance.com
Flagship merchandise of Revance Therapeutics Inc

This indicator represents the weighted average target price of Revance Therapeutics (RVNC) shares, calculated based on daily valuation revisions from leading investment houses to determine fundamental growth potential. The price action of the investment houses' weighted average target serves as a risk mitigation tool, reflecting market expectations for the productivity of the RVNC innovation cycle and the upcoming clinical trial results for Daxxify.

Competitors of Revance Therapeutics

KRYS (krystalbio.com) - Fair Value Consensus|Apogee Therapeutics, Inc. - Consensus Target|Arcutis - Price Target Chart|VCEL - Price Target Chart|ORKA (Oruka Pharma) - Broker Consensus Forecast|SMTI: Analyst Consensus Forecast|Consensus Target DBV Technologies|Price Target Chart Solesence Beauty|Journey Medical Corp. - Forecast Levels Chart|Analyst Consensus Forecast FBRX|EMPG (Empro Corporation) - Fair Value Consensus|Analyst Consensus Forecast SLGL (Sol-Gel Technologies)|Analyst Consensus Forecast AXIL Brands Inc AXIL|MDCX - Price Target Chart|Fair Value Consensus VRCA (Verrica Pharmaceuticals)|hoththerapeutics.com (HOTH) - Price Target Chart|Consensus Target Biofrontera|VYNE (VYNE Therapeutics, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Sonoma Pharma|Consensus Target QNRX (Quoin Pharmaceuticals)|AZTR (Azitra Inc) - Fair Value Consensus|Price Target Chart Dermata DRMA|Analyst Median Target Elevai Corp (ELAB)